Epstein-Barr virus and Burkitt lymphoma

Postgraduate Medical Journal

Volumn 84, Issue 993, 2008, Pages 372-377

  Brady, G ^a   MacArthur, G J ^a   Farrell, P J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BURKITT LYMPHOMA; CELL SURVIVAL; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENE TRANSLOCATION; HUMAN; IMMUNE DEFICIENCY; MALARIA; NONHUMAN; ONCOGENE MYC; PATHOGENESIS; REVIEW; SOMATIC MUTATION; SPONTANEOUS MUTATION; VIRUS INFECTION;

BURKITT LYMPHOMA; CELL SURVIVAL; EPSTEIN-BARR VIRUS INFECTIONS; GENES, MYC; HUMANS; MALARIA; TRANSLOCATION, GENETIC;

EID: 51449088306     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2007.047977     Document Type: Review

References (133)

1. Ferry JA. Burkitt's lymphoma: clinicopathologic features and differential diagnosis. Oncologist 2006;11:375-83.
2. Pattle SB, Farrell PJ. The role of Epstein-Barr virus in cancer. Expert Opin Biol Ther 2006;6:1193-205.
3. van den Bosch CA. Is endemic Burkitt's lymphoma an alliance between three infections and a tumour promoter? Lancet Oncol 2004;5:738-46.
4. Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood 2004;104:3009-20.
5. Anwar N, Kingma DW, Bloch AR, et al. The investigation of Epstein-Barr viral sequences in 41 cases of Burkitt's lymphoma from Egypt: epidemiologic correlations. Cancer 1995;76:1245-52.
6. Araujo I, Foss HD, Hummel M, et al. Frequent expansion of Epstein-Barr virus (EBV) infected cells in germinal centres of tonsils from an area with a high incidence of EBV-associated lymphoma. J Pathol 1999;187:326-30.
7. Klumb CE, Hassan R, De Oliveira DE, et al. Geographic variation in Epstein-Barr virus-associated Burkitt's lymphoma in children from Brazil. Int J Cancer 2004;108:66-70.
8. Rochford R, Cannon MJ, Moormann AM. Endemic Burkitt's lymphoma: a polymicrobial disease? Nat Rev Microbiol 2005;3:182-7.
9. Powles T, Matthews G, Bower M. AIDS related systemic non-Hodgkin's lymphoma. Sex Transm Infect 2000;76:335-41.
10. Sariban E, Donahue A, Magrath IT. Jaw involvement in American Burkitt's Lymphoma. Cancer 1984;53:1777-82.
11. Mwanda OW. Clinical characteristics of Burkitt's lymphoma seen in Kenyan patients. East Afr Med J 2004:S78-89.
12. Iversen U, Iversen OH, Bluming AZ, et al. Cell kinetics of African cases of Burkitt lymphoma. A preliminary report. Eur J Cancer 1972;8:305-8.
13. Rowe M, Rooney CM, Rickinson AB, et al. Distinctions between endemic and sporadic forms of Epstein-Barr virus-positive Burkitt's lymphoma. Int J Cancer 1985;35:435-41.
14. Rowe M, Rooney CM, Edwards CF, et al. Epstein-Barr virus status and tumour cell phenotype in sporadic Burkitt's lymphoma. Int J Cancer 1986;37:367-73.
15. Wiels J, Lenoir GM, Fellous M, et al. A monoclonal antibody with anti-Burkitt lymphoma specificity. I. Analysis of human haematopoietic and lymphoid cell lines. Int J Cancer 1982;29:653-8.
16. Natkunam Y, Lossos IS, Taidi B, et al. Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. Blood 2005;105:3979-86.
17. Bellan C, Lazzi S, De Falco G, et al. Burkitt's lymphoma: new insights into molecular pathogenesis. J Clin Pathol 2003;56:188-92.
18. Bellan C, Lazzi S, Hummel M, et al. Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas. Blood 2005;106:1031-6.
19. Chapman CJ, Mockridge CI, Rowe M, et al. Analysis of VH genes used by neoplastic B cells in endemic Burkitt's lymphoma shows somatic hypermutation and intraclonal heterogeneity. Blood 1995;85:2176- 81.
20. Chapman CJ, Zhou JX, Gregory C, et al. VH and VL gene analysis in sporadic Burkitt's lymphoma shows somatic hypermutation, intraclonal heterogeneity, and a role for antigen selection. Blood 1996;88:3562-8.
21. Chapman CJ, Wright D, Stevenson FK. Insight into Burkitt's lymphoma from immunoglobulin variable region gene analysis. Leuk Lymphoma 1998;30:257-67.
22. Isobe K, Tamaru J, Nakamura S, et al. VH gene analysis in sporadic Burkitt's lymphoma: somatic mutation and intraclonal diversity with special reference to the tumor cells involving germinal center. Leuk Lymphoma 2002;43:159-64.
23. Tamaru J, Hummel M, Marafioti T, et al. Burkitt's lymphomas express VH genes with a moderate number of antigen-selected somatic mutations. Am J Pathol 1995;147:1398-407.
24. Haluska FG, Finver S, Tsujimoto Y, et al. The t(8; 14) chromosomal translocation occurring in B-cell malignancies results from mistakes in V-D-J joining. Nature 1986;324:158-61.
25. Haluska FG, Tsujimoto Y, Croce CM. The t(8; 14) chromosome translocation of the Burkitt lymphoma cell line Daudi occurred during immunoglobulin gene rearrangement and involved the heavy chain diversity region. Proc Natl Acad Sci USA 1987;84:6835-9.
26. Hikida M, Mori M, Takai T, et al. Reexpression of RAG-1 and RAG-2 genes in activated mature mouse B cells. Science 1996;274:2092-4.
27. Han S, Zheng B, Schatz DG, et al. Neoteny in lymphocytes: Rag1 and Rag2 expression in germinal center B cells. Science 1996;274:2094-7.
28. Magrath IT. African Burkitt's lymphoma. History, biology, clinical features, and treatment. Am J Pediatr Hematol Oncol 1991;13:222- 46.
29. Lane HC, Masur H, Edgar LC, et al. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med 1983;309:453-8.
30. Greenwood BM, Vick RM. Evidence for a malaria mitogen in human malaria. Nature 1975;257:592-4.
31. Gabrielsen AA Jr, Jensen JB. Mitogenic activity of extracts from continuous cultures of Plasmodium falciparum. Am J Trop Med Hyg 1982;31:441-8.
32. Donati D, Mok B, Chene A. et al. Increased B cell survival and preferential activation of the memory compartment by a malaria polyclonal B cell activator. J Immunol 2006;177:3035-44.
33. Nakajima K, Martinez-Maza O, Hirano T, et al. Induction of IL-6 (B cell stimulatory factor-2/IFN-beta 2) production by HIV. J Immunol 1989;142:531-6.
34. Masood R, Zhang Y, Bond MW, et al. Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-cell lymphoma. Blood 1995;85:3423-30.
35. Masood R, Lunardi-lskandar Y, Moudgil T, et al. IL-10 inhibits HIV-1 replication and is induced by tat. Biochem Biophys Res Commun 1994;202:374-83.
36. Breen EC, Rezai AR, Nakajima K, et al. Infection with HIV is associated with elevated IL-6 levels and production. J Immunol 1990;144:480-4.
37. Ueda C, Nishikori M, Kitawaki T, et al. Coexistent rearrangements of c-MYC, BCL2, and BCL6 genes in a diffuse large B-cell lymphoma. Int J Hematol 2004;79:52-4.
38. Avet-Loiseau H, Gerson F, Magrangeas F, et al. Reanangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 2001;98:3082-6.
39. Kanda-Akano Y, Nomura K, Fujita Y, et al. Molecular-cvtogenetic characterization of non-Hodgkin's lymphoma with double and cryptic translocations of the immunoglobulin heavy chain gene. Leuk Lymphoma 2004;45:1559-67.
40. Shou Y, Martelli ML, Gabrea A, et al. Diverse karyotypc abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci USA 2000;97:228-33.
41. Adams JM, Harris AW, Pinkert CA, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985;318:533-8.
42. Nussenzweig MC. Schmidt EV, Shaw AC, et al. A human immunoglobulin gene reduces the incidence of lymphomas in c-Myc-bearing transgenic mice. Nature 1988;336:446-50.
43. Park SS, Kim JS, Tessarollo L, et al. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. Cancer Res 2005;65:1306-15.
44. Shen-Ong GL. Keath EJ, Piccoli SP, et al. Novel myc oncogene RNA from abortive immunoglobulin-gene recombination in mouse plasmacytomas. Cell 1982;31:443-52.
45. Pear WS, Wahlstrom G, Nelson SF, et al. 6;7 chromosomal translocation in spontaneously arising rat immunocytomas: evidence for c-myc breakpoint clustering and correlation between isotypic expression and the c-myc target. Mol Cell Biol 1988;8:441-51.
46. Eisenman RN. Deconstructing myc. Genes Dev 2001;15:2023-30.
47. Persson H, Hennighausen L, Taub R. et al. Antibodies to human c-myc oncogene product: evidence of an evolutionarily conserved protein induced during cell proliferation. Science 1984;225:687-93.
48. Sarid J, Halazonetis TD, Murphy W, et al. Evolutionarily conserved regions of the human c-myc protein can be uncoupled from transforming activity, Proc Natl Acad Sci USA 1987;84:170-3.
49. Schreiber-Agus N, Alland L, Muhle R, et al. A biochemical and biological analysis of Myc superfamily interactions. Curr Top Microbiol Immunol 1997;224:159-68.
50. Prendergast GC, Ziff EB. A new bind for Myc. Trends Genet 1992;8:91-6.
51. Blackwood EM, Eisenman RN. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 1991;251:1211-7.
52. Coller HA, Grandori C, Tamayo P, et al. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci USA 2000;97:3260-5.
53. Li Z, Van Calcar S, Qu C, et al. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci USA 2003;100:8164-9.
54. Spencer CA, Groudine M. Control of c-myc regulation in normal and neoplastic cells. Adv Cancer Res 1991;56:1-48.
55. Taub R, Moulding C, Battey J, et al. Activation and somatic mutation of the translocated c-myc gene in Burkitt lymphoma cells. Cell 1984;36:339-48.
56. Sears R, Leone G, DeGregori J, et al. Has enhances Myc protein stability. Mol Cell 1999;3:169-79.
57. Sears R, Nuckolls F, Haura E, et al. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 2000;14:2501-14.
58. Shiramizu B, Barnga F, Neequaye J, et al. Patterns of chromosomal breakpoint locations in Burkitt's lymphoma: relevance to geography and Epstein-Barr virus association. Blood 1991;77:1516-26.
59. Wilda M, Busch K, Klose I, et al. Level of MYC overexpression in pediatric Burkitt's lymphoma is strongly dependent on genomic breakpoint location within the MYC locus. Genes Chromosomes Cancer 2004;41:178-82.
60. Ji L, Arcinas M, Boxer LM. NF-kappa B sites function as positive regulators of expression of the translocated c-myc allele in Burkitt's lymphoma. Mol Cell Biol 1994;14:7967-74.
61. Ji L, Arcinas M, Boxer LM. The transcription factor. Nm23H2. binds to and activates the translocated c-myc allele in Burkitt's lymphoma. J Bid Chem 1995;270:13392-8.
62. Hortnagel K, Mautner J, Strobl LJ, et al. The role of immunoglobulin kappa elements in c-myc activation. Oncogene 1995;10:1393-401.
63. Strobl LJ, Eick D. Hold back of RNA polymerase II at the transcription start site mediates down-regulation of c-myc in vivo. Embo J 1992;11:3307-14.
64. Strobl LJ, Kohlhuber F, Mautner J, et al. Absence of a paused transcription complex from the c-myc P2 promoter of the translocation chromosome in Burkitt's lymphoma cells: implication for the c-myc P1/P2 promoter shift. Oncogene 1993;8:1437-47.
65. ar-Rushdi A, Nishikura K, Erikson J, et al. Differential expression of the translocated and the untranslocated c-myc oncogene in Burkitt lymphoma. Science 1983;222:390-3.
66. Hayday AC, Gillies SD, Saito H, et al. Activation of a translocated human c-myc gene by an enhancer in the immunoglobulin heavy-chain locus. Nature 1984;307:334-40.
67. Nishikura K, ar-Rushdi A, Erikson J, et al. Differential expression of the normal and of the translocated human c-myc oncogenes in B cells. Proc Natl Acad Sci USA 1983;80:4822-6.
68. Dunrtick W, Shell BE. Dery C. DNA sequences near the site of reciprocal recombination between a c-myc oncogene and an Immunoglobulin switch region. Proc Natl Acad Sci USA 1983;80:7269-73.
69. Gerondakis S, Cory S. Adams JM. Translocation of the myc cellular oncogene to the immunoglobulin heavy chain locus in murine plasmacytomas is an imprecise reciprocal exchange. Cell 1984;36:973-B2.
70. Roix JJ, McQueen PG, Munson PJ, et al. Spatial proximity of translocation-prone gene loci in human lymphomas. Nat Genet 2003;34:287-91.
71. Wiener F, Silva S, Sugiyama H, et al. The "missing" mouse plasmacytoma (MPC) associated translocation T(15;16) occurs repeatedly in new MPC induction systems. Genes Chromosomes Cancer 1990;2:36-43.
72. Silva S, Kovalchuk AL, Kim JS, et al. BCL2 accelerates inflammation-induced BALB/ c plasmacytomas and promotes novel tumors with coexisting T(12;15) and T(6; 15) translocations. Cancer Res 2003;63:8656-63.
73. Cesarman E, Dalla-Favera R, Bentley D. et al. Mutations in the first exon are associated with altered transcription of c-myc in Burkitt lymphoma. Science 1987;238:1272-5.
74. Yu BW, Ichinose I, Bonham MA, et al. Somatic mutations in c-myc intron I cluster in discrete domains that define protein binding sequences. J Biol Chem 1993;268:19586-92.
75. Zajac-Kaye M, Gelmann EP, Levens D. A point mulation in the c-myc locus ofa Burkitt lymphoma abolishes binding of a nuclear protein Science 1988;240:1776-80.
76. Gregory MA, Hann SR. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol 2000;20:2423-35.
77. Packham G, Cleveland JL. c-Myc and apoptosis. Biochim Biophys Acta 1995;1242:11-28.
78. Cherney BW, Bhatia KG, Sgadari C, et al. Role of the p53 tumor suppressor gene in the tumorigenicity of Burkitt's lymphoma cells. Cancer Res 1997;57:2508-15.
79. Eischen CM, Weber JD, Roussel MF, et al. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced tymphomagenesis. Genes Dev 1999;13:2658-69.
80. Quelle DE, Zindy F, Ashmun RA, et al. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995;83:993-1000.
81. Kamijo T, Weber JD, Zambetti G, et al. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 1998;95:8292-7.
82. Pomerantz J, Schreiber-Agus N, Liegeois NJ, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998;92:713-23.
83. Stott FJ, Bates S, James MC, et al. The alternative product from the human COKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. Emtio J 1998;17:5001-14.
84. Barak Y, Juven T, Haffner R, et al. mdm2 expression is induced by wild type p53 activity. Embo J 1993;12:461-8.
85. Zindy F, Eischen CM, Randle DH, et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 1998;12:2424-33.
86. O'Connor L, Strasser A, O'Reilly LA, et al. Bim: a novel member of the Bcl-2 family that promotes apoptosis. Embo J 1998;17:384-95.
87. Hemann MT, Bric A, Teruya-Feldstein J, et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 2005;436:807-11.
88. Clybouw C, McHichi B, Mouhamad S, et al. EBV infection of human B lymphocytes leads to down-regulation of Bim expression: relationship to resistance to apoptosis. J Immunol 2005;175:2968-73.
89. Leao M, Anderton E, Wade M, et al. Epstein-Barr virus-induced resistance to drugs that activate the mitotic spindle assembly checkpoint in Burkitt's lymphoma cells. J Virol 2007;81:248-60.
90. Harvey DM, Levine AJ. p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes Dev 1991;5:2375-85.
91. Zindy F, Quelle DE, Roussel MF, et al. Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 1997;15:203-11.
92. Farrell PJ, Allan GJ, Shanahan F, et al. p53 is frequently mutated in Burkitt's lymphoma cell lines. Embo J 1991;10:2879-87.
93. Gaidano G, Ballerini P, Gong JZ, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1991;88:5413-7.
94. Lindstrom MS, Klangby U, Wiman KG. p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53. Oncogene 2001;20:2171-7.
95. lonov Y, Le X, Tunquist BJ, et al. Pim-1 protein kinase is nuclear in Burkitt's lymphoma: nuclear localization is necessary for its biologic effects. Anticancer Res 2003;23:167-78.
96. Cinti C, Leoncini L, Nyongo A, et al. Genetic alterations of the retinoblastoma-related gene RB2/p130 identify different pathogenetic mechanisms in and among Burkitt's lymphoma subtypes. Am J Pathol 2000;156:751-60.
97. Cinti C, Claudio PP, Howard CM, et al. Genetic alterations disrupting the nuclear localization of the retinoblastoma-related gene RB2/p130 in human tumor cell lines and primary tumors. Cancer Res 2000;60:383-9.
98. Neri A, Barriga F, Inghirami G, et al. Epstein-Barr virus infection precedes clonal expansion in Burkitt's and acquired immunodeficiency syndrome-associated lymphoma. Blood 1991;77:1092-5.
99. Pagano JS, Blaser M, Buendia MA, et al. Infectious agents and cancer: criteria for a causal relation. Semin Cancer Biol 2004;14:453-71.
100. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 2001;1:75-82.
101. Tao Q, Robertson KD, Manns A, et al. Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue. Blood 1998;91:1373-81.
102. Rowe M, Rowe DT, Gregory CD, et al. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. Embo J 1987;6:2743-51.
103. Kelly G, Bell A, Rickinson A. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2.Nat Med 2002;8:1098-104.
104. Rowe M, Khanna R, Jacob CA, et al. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur J Immunol 1995;25:1374-84.
105. Khanna R, Burrows SR, Argaet V, et al. Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line, Int Immunol 1994;6:639-45.
106. Hammerschmidt W, Sugden B. Epstein-Barr virus sustains Burkitt's lymphomas and Hodgkin's disease. Trends Mol Med 2004;10:331-6.
107. Wilson JB, Bell JL, Levine AJ. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. Embo J 1996;15:3117-26.
108. Kennedy G, Komano J, Sugden B. Epstein-Barr virus provides a survival factor to Burkitt's lymphomas. Proc Natl Acad Sci USA 2003;100:14269-74.
109. Komano J, Sugiura M, Takada K. Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata. J Virol 1998;72:9150-6.
110. Komano J, Maruo S, Kurozumi K, et al. Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata. J Virol 1999;73:9827-31.
111. Ruf IK, Rhyne PW, Yang C, et al. Epstein-Barr virus small RNAs potentiate tumorigenicity of Burkitt lymphoma cells independently of an effect on apoptosis. J Virol 2000;74:10223-8.
112. Nanbo A, Yoshiyama H, Takada K. Epstein-Barr virus-encoded poly(A)- RNA confers resistance to apoptosis mediated through Fas by blocking the PKR pathway in human epithelial intestine 407 cells. J Virol 2005;79:12280-5.
113. Sharp TV, Schwemmle M, Jeffrey I, et al. Comparative analysis of the regulation of the interferon-inducible protein kinase PKR by Epstein-Barr virus RNAs EBER-1 and EBER-2 and adenovirus VAI RNA. Nucleic Acids Res 1993;21:4483-90.
114. Nanbo A, Inoue K, Adachi-Takasawa K, et al. Epstein-Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt's lymphoma. Embo J 2002;21:954-65.
115. Elia A, Laing KG, Schofield A, et al. Regulation of the double-stranded RNA-dependent protein kinase PKR by RNAs encoded by a repeated sequence in the Epstein-Barr virus genome. Nucleic Acids Res 1996;24:4471-8.
116. McKenna SA, Kim I, Liu CW, et al. Uncoupling of RNA binding and PKR kinase activation by viral inhibitor RNAs. J Mol Biol 2006;358:1270-85.
117. Kitagawa N, Goto M, Kurozumi K, et al. Epstein-Barr virus-encoded poly(A)(-) RNA supports Burkitt's lymphoma growth through interleukin-10 induction. Embo J 2000;19:6742-50.
118. Ogden CA, Pound JD, Batth BK, et al. Enhanced apoptotic cell clearance capacity and B cell survival factor production by IL-10-activated macrophages: implications for Burkitt's lymphoma. J Immunol 2005;174:3015-23.
119. Cai X, Schafer A, Lu S, et al. Epstein-Barr virus microRNAs are evolutionary conserved and differentially expressed. PLoS Pathog 2006;2:e23.
120. Kelly GL, Milner AE, Baldwin GS, et al. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells. Proc Natl Acad Sci USA 2006;103:14935-40.
121. Niedobitek G, Agathanggelou A, Rowe M, et al. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma. Blood 1995;86:659-65.
122. Xue SA, Labrecque LG, Lu QL, et al. Promiscuous expression of Epstein-Barr virus genes in Burkitt's lymphoma from the central African country Malawi. Int J Cancer 2002;99:635-43.
123. Moss DJ, Burrows SR, Castelino DJ, et al. A comparison of Epstein-Barr virus-specific T-cell immunity in malaria-endemic and -nonendemic regions of Papua New Guinea. Int J Cancer 1983;31:727-32.
124. Whittle HC, Brown J, Marsh K, et al. The effects of Plasmodium falciparum malaria on immune control of B lymphocytes in Gambian children. Clin Exp Immunol 1990;80:213-8.
125. Whittle HC, Brown J, Marsh K, et al. T-cell control of Epstein-Barr virus-infected B cells is lost during P falciparum malaria. Nature 1984;312:449-50.
126. Lam KM, Syed N, Whittle H, et al. Circulating Epstein-Barr virus-carrying B cells in acute malaria. Lancet 1991;337:876-8.
127. Moormann AM, Chelimo K, Sumba OP, et al. Exposure to holoendemic malaria results in elevated Epstein-Barr virus loads in children. J Infect Dis 2005;191:1233-8.
128. Yone CL, Kube D, Kremsner PG, et al. Persistent Epstein-Barr viral reactivation in young African children with a history of severe Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 2006;100:669-76.
129. Rasti N, Falk Kl, Donati D, et al. Circulating Epstein-Barr virus in children living in malaria-endemic areas. Scand J Immunol 2005;61:461-5.
130. Burkitt DP. The discovery of Burkitt's lymphoma. Cancer 1983;51:1777-86.
131. Lyke KE, Burges R, Cissoko Y, et al. Serum levels of the proinflammatory cytokines interleukin-1 beta (IL-1 beta), IL-6, IL-8, IL-10, tumor necrosis factor alpha, and IL-12(p70) in Malian children with severe Plasmodium falciparum malaria and matched uncomplicated malaria or healthy controls. Infect Immun 2004;72:5630-7.
132. Artavanis-Tsakonas K, Tongren JE, Riley EM. The war between the malaria parasite and the immune system: immunity, immunoregulation and immunopathology. Clin Exp Immunol 2003;133:145-52.
133. Crawford DH. Biology and disease associations of Epstein-Barr virus. Philos Trans R Soc Land B Biol Sci 2001;356:461-73.